Larazotide Protocol: Complete Cycling & Dosing Guide

Overview

Larazotide acetate (AT-1001) is a synthetic octapeptide designed to regulate intestinal tight junction integrity by antagonizing zonulin, the endogenous protein responsible for controlling paracellular permeability across the gut epithelial barrier. Its primary clinical application is reducing gastrointestinal symptoms in celiac disease patients by preventing gliadin peptide passage and subsequent immune activation.

Unlike compounds developed for performance enhancement or fat loss, larazotide operates through a highly specific mechanism: stabilizing occludin and claudin protein complexes at tight junctions to block unwanted antigen passage into the lamina propria. This upstream immune modulation distinguishes it from symptomatic treatments and positions it as a barrier-restoration compound.

Key Distinction: Larazotide has no demonstrated efficacy for fat loss, cognitive enhancement, or general performance metrics. Its evidence base supports use in celiac disease symptom management and emerging applications in post-inflammatory conditions. Protocol design should reflect this specific therapeutic window.

Standard Protocol

Baseline Dosing

Standard dose: 0.5 mg (500 mcg) orally, three times daily
Frequency: Every 8 hours, approximately
Cycle length: 12 weeks (aligns with clinical trial duration and safety data)
Rest period: 4 weeks between cycles
Total monthly cost: $80–$220 depending on source and purity

The 0.5 mg three-times-daily regimen is the dose supported by Phase 3 celiac disease clinical trials showing statistically significant symptom reduction (P=0.022 on GI symptom scoring; 26% reduction in symptomatic days; 50% reduction in abdominal pain lasting ≥6 weeks).

Why This Dose Structure Works

The 0.5 mg dose—not 1 mg or 2 mg—demonstrated the most consistent efficacy in the largest RCT (n=340). Higher doses (1 mg, 2 mg) did not provide additional benefit and sometimes showed reduced efficacy, suggesting an optimal tissue concentration window. This dose-response relationship argues against dose escalation strategies common with other compounds.

Timing Relative to Meals

Critical protocol element: Administer larazotide 30 minutes before meals.

This pre-meal window allows the peptide to reach the small intestinal epithelium and establish tight junction stabilization before dietary antigens (especially gluten if celiac disease is present) encounter the barrier. Taking it with food or immediately after food reduces bioavailability and clinical efficacy.

Practical schedule:

• Dose 1: 6:00 AM (30 min before breakfast)
• Dose 2: 1:00 PM (30 min before lunch)
• Dose 3: 6:30 PM (30 min before dinner)

Goal-Specific Protocols

Protocol A: Celiac Disease Symptom Management (Primary Indication)

Cycle structure: 12 weeks on, 4 weeks off

Weeks 1–12:

• 0.5 mg, three times daily, 30 minutes before meals
• Continue strict gluten-free diet (larazotide is adjunctive, not a substitute)
• Track GI symptoms daily: abdominal pain (0–10 scale), stool consistency, bloating, fatigue

Weeks 13–16: Off-cycle (rest period)

Assessment point: End of week 6 and week 12

• Reduction in symptomatic days expected by week 6 (26% mean reduction by 12 weeks in trials)
• 50% abdominal pain reduction for sustained periods (≥6 weeks) indicates positive response
• Anti-tTG antibody titers may remain unchanged or slowly decline; intestinal histology typically shows no reversal within 12 weeks

Repeat cycles: 3–4 times per year with 4-week rest periods between

Protocol B: Post-Inflammatory Condition Recovery (Emerging Indication)

Based on small RCT data in post-COVID multisystem inflammatory syndrome (n=12), this protocol targets inflammation-driven GI dysfunction and systemic immune dysregulation.

Cycle structure: 8 weeks on, 6 weeks off

Weeks 1–8:

• 0.5 mg, three times daily (same dosing as Protocol A)
• Monitor inflammatory markers if access available: IL-6, IFN-γ, C-reactive protein
• Track GI symptoms and systemic symptoms (fatigue, brain fog, joint pain)

Weeks 9–14: Off-cycle with longer rest period to assess residual inflammation

Expected outcome: Faster symptom resolution compared to no intervention; spike antigen (or viral marker) clearance accelerated in observed cases

Repeat cycles: 2–3 times per year only; post-inflammatory conditions typically require extended recovery periods

Protocol C: Barrier Integrity Restoration (Leaky Gut Syndrome)

This is an off-label application without direct RCT evidence but mechanistically sound for conditions involving compromised tight junction function.

Cycle structure: 10 weeks on, 3 weeks off

Weeks 1–10:

• 0.5 mg, three times daily, 30 minutes before meals
• Eliminate known gut irritants: NSAIDs, excessive alcohol, high-dose probiotics initially
• Assess by symptoms: reduced bloating, improved stool consistency, decreased food sensitivities
• Consider stool calprotectin as biomarker if available (should decrease if inflammation is resolving)

Weeks 11–13: Off-cycle

Warning: Larazotide specifically targets zonulin antagonism; if barrier dysfunction is secondary to dysbiosis, NSAID use, or food sensitivity (not zonulin dysregulation), response will be suboptimal. Proper diagnosis before use is essential.

How to Administer Step-by-Step

Sourcing and Verification

1. Obtain larazotide from a research peptide vendor with third-party testing (HPLC, mass spectrometry)
2. Request Certificate of Analysis confirming peptide purity ≥95% and identity
3. Verify no bacterial endotoxin contamination (LAL testing)
4. Confirm lyophilized (freeze-dried) form for stability

Reconstitution (if supplied as powder)

Larazotide acetate is often supplied as a lyophilized powder requiring reconstitution:

1. Calculate total volume needed for 12-week cycle: 0.5 mg × 3 doses × 84 days = 126 mg total
2. Obtain bacteriostatic water (NOT sterile saline—bacteriostatic preserves peptide integrity)
3. Add bacteriostatic water to vial in 10:1 ratio by volume (e.g., 1.26 mL bacteriostatic water per 126 mg peptide)
4. Allow 2–3 minutes for complete dissolution; do not shake vigorously (denatures peptide)
5. Gently roll vial between palms until fully dissolved
6. Resulting concentration: ~100 mcg/mL (0.5 mg = 5 mL per dose)

Oral Administration (Most Common)

If supplied as capsules or tablets (0.5 mg), simply swallow with 250 mL water on an empty stomach, 30 minutes before meals.

If using liquid reconstitution:

1. Measure 5 mL of reconstituted solution using a sterile syringe (0.5 mg dose)
2. Take orally; hold in mouth briefly to allow buccal absorption to begin
3. Swallow with minimal water (peptides are sensitive to gastric acid; rapid transit may reduce bioavailability)
4. Wait 30 minutes before eating

Storage

• Lyophilized powder: Room temperature, protected from light and moisture; stable for 24 months
• Reconstituted solution: Refrigerated (2–8°C) in sterile vial; stable for 14 days maximum
• Do not freeze reconstituted larazotide (ice crystal formation damages peptide structure)

Cycle Example: Week-by-Week Schedule

12-Week Celiac Disease Protocol

What to Expect: Timeline of Effects

Week 1–2: Acclimation Phase

• Headache: Most common adverse event (14–18% of subjects); typically mild, resolves within 3–5 days
• Nausea: If present, usually related to taking on completely empty stomach; mitigate by eating within 45 minutes of dose
• Abdominal sensations: May transiently worsen as barrier begins restoring and previously "silent" inflammation becomes symptomatic; expect mild cramping, bloating

Action: Do not discontinue; symptoms are dose-independent and not predictive of long-term tolerability.

Week 3–6: Early Response Phase

• GI symptom score decline: Progressive reduction in diarrhea frequency and abdominal pain severity
• Energy stabilization: Fatigue related to chronic inflammation begins improving
• Stool consistency: Normalization if diarrhea was baseline symptom
• Bloating reduction: Less distension, improved appetite

Expected magnitude: 15–20% reduction in symptom severity by week 4; 26% by week 6 in responders

Week 7–12: Plateau Phase

• Sustained symptom reduction: Improvements from weeks 3–6 maintain and marginally progress
• Anti-inflammatory markers: If measured, IL-6 and IFN-γ may decline slowly; anti-tTG antibodies typically stable (don't expect seroconversion)
• Gluten challenge resilience (if celiac): Accidental gluten exposure may produce less severe GI response than baseline

Expected magnitude: 26–50% reduction in symptom days and abdominal pain by week 12

Week 13–16: Off-Cycle Period

• Symptom rebound: Typical pattern is gradual return to baseline over 4 weeks if underlying condition (e.g., celiac disease) untreated
• Assessment marker: Durability of improvement despite off-cycle indicates partial mucosal healing vs. symptomatic suppression
• Planning: Decide on re-entry based on symptom trajectory

Common Protocol Mistakes

Mistake 1: Dose Escalation

The Error: Assuming higher doses (1 mg, 2 mg) improve efficacy faster

Why It Fails: Phase 3 celiac data showed reduced efficacy at 1 mg and 2 mg compared to 0.5 mg. This is not a dose-response relationship; it's an inverted-U curve, likely due to receptor saturation or off-target binding at higher concentrations.

Correction: Never exceed 0.5 mg per dose. If 0.5 mg TID shows no response by week 6, the issue is likely poor bioavailability (meal timing, absorption) or wrong diagnosis, not insufficient dose.

Mistake 2: Taking With Food

The Error: Taking larazotide simultaneously with meals or immediately after

Why It Fails: Peptide bioavailability is compromised; buffering by stomach contents reduces transit to small intestine; co-digestion with food competes for absorption

Correction: Strict 30-minute pre-meal window. Set phone reminders if needed. If you forget and eat within 30 minutes, skip that dose rather than taking it post-meal.

Mistake 3: Cycling Too Frequently Without Rest Periods

The Error: Running continuous larazotide without 4-week off-cycles

Why It Fails: No safety data beyond 12 weeks continuous; risk of adaptation, loss of efficacy, or undetected side effects accumulation

Correction: Mandatory 4-week rest every 12 weeks. Use off-cycle to assess durability of improvement and reset any potential tolerance.

Mistake 4: Unrealistic Expectations for Antibody Conversion

The Error: Expecting anti-tTG IgA to become negative within 12 weeks

Why It Fails: Larazotide prevents new antigen presentation; it does not reverse established adaptive immunity. Seroconversion requires months to years of strict gluten avoidance plus mucosal healing.

Correction: Use symptom reduction and quality-of-life metrics, not serology, as primary efficacy endpoints.

Mistake 5: Sourcing From Unverified Vendors

The Error: Purchasing larazotide from non-research suppliers without third-party testing

Why It Fails: Peptide integrity cannot be verified; contamination risk; inactive or misidentified product

Correction: Always request and review Certificate of Analysis. Reputable vendors provide HPLC purity data and endotoxin testing. Budget $150–$220/month for verified product.

How to Stack With Other Compounds

Larazotide's mechanism (tight junction stabilization) is orthogonal to most performance compounds but synergistic with certain gut-supportive stacks.

Stack A: Celiac Disease Optimization

Larazotide (0.5 mg TID) + Bone broth collagen (20g daily) + L-glutamine (5g TID, between meals)

Rationale: Larazotide restores barrier architecture; collagen provides structural substrate; L-glutamine fuels enterocyte metabolism. No pharmacokinetic interactions.

Timing: Larazotide 30 min pre-meal; collagen/L-glutamine separate from larazotide by ≥1 hour

Expected synergy: Faster epithelial healing; greater symptom reduction by week 8

Stack B: Post-Inflammatory Recovery

Larazotide (0.5 mg TID) + Quercetin (500 mg BID) + Omega-3 fatty acids (2–3g EPA+DHA daily)

Rationale: Larazotide restores barrier; quercetin is mast cell stabilizer (reduces local inflammation); omega-3s dampen systemic inflammation. Mechanistically complementary.

Timing: All compounds can be taken simultaneously with meals (larazotide 30 min before; others with meals)

Expected synergy: Faster IL-6 and IFN-γ decline; accelerated recovery timeline

Stack C: General Leaky Gut Protocol

Larazotide (0.5 mg TID) + Zinc carnosine (150 mg TID, with meals) + Probiotics (strain-specific, high CFU, taken 2+ hours away from larazotide)

Rationale: Larazotide targets zonulin pathway; zinc carnosine strengthens mucosal barrier directly; probiotics restore dysbiotic contributors to barrier dysfunction.

Important: Do not co-administer probiotics with larazotide (peptide absorption competition). Separate by minimum 2 hours.

Timing: Larazotide 30 min pre-meal; zinc carnosine with meals; probiotics 2 hours post-larazotide

Compounds to Avoid Stacking

• NSAIDs: Counterproductive; NSAIDs increase zonulin and gut permeability. Defeats larazotide mechanism.
• High-dose antibiotics during cycle: Dysbiosis worsens barrier function; delay larazotide start until 2 weeks post-antibiotic if possible.
• Excessive alcohol (>2 drinks/day): Alcohol increases zonulin and permeability independently; antagonizes larazotide mechanism.

Protocol Quick Reference Table